Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

Last updated: February 17, 2012
Sponsor: Bausch & Lomb Incorporated
Overall Status: Completed

Phase

3

Condition

Eye Disorders/infections

Allergy

Treatment

N/A

Clinical Study ID

NCT01435460
634
  • Ages > 18
  • All Genders

Study Summary

This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects who are diagnosed with acute SAC and experience at least grade 4 ocularitching and at least grade 2 bulbar conjunctival injection (redness) in each eye dueto seasonal allergy at Visit 1.

Exclusion

Exclusion Criteria:

  • Subjects who have a known hypersensitivity to the study medications or theircomponents or contraindications to ocular corticosteroids.

  • Subjects who use any of the disallowed medications throughout the duration of thestudy and during the period indicated prior to Visit 1.

  • Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye orany type of glaucoma.

  • Subjects who have a history of any severe/serious ocular pathology or medicalcondition that could result in the subject's inability to complete the study or affectthe subject's safety or trial parameters.

Study Design

Total Participants: 300
Study Start date:
August 01, 2010
Estimated Completion Date:
May 31, 2011

Connect with a study center

  • Bausch & Lomb Singapore

    Singapore, 556741
    Singapore

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.